Atlas Trials

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Clinical trial NCT02150213 · COMPLETED

Trial details

NCT number
NCT02150213
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Adrenocortical AdenomaEndometrial Stromal Sarcomas
Start date
2014-08-01
Primary completion
2015-09-01
Enrollment
59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.